This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Axovant (AXGT) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Axovant's (AXGT) first-quarter fiscal 2019 earnings call, investor focus will be on its progress with the investigational pipeline candidates designed to treat debilitating neurological diseases.
Eton's Ophthalmic Solution Candidate Gets CRL, Shares Fall
by Zacks Equity Research
Eton's (ETON) partner receives complete response letter for a regulatory application seeking approval of its pipeline candidate, EM-100, as a treatment for ocular itching.
Axovant (AXGT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Axovant (AXGT) closed the most recent trading day at $7.38, moving +0.68% from the previous trading session.
Will Axovant Sciences Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Axovant Sciences.
Sarepta Stock Up Almost 40% This Year So Far: Here's Why
by Zacks Equity Research
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is nearing approval. The company is also developing gene therapies.
Perrigo Completes Ranir Acquisition, Raises '19 Guidance
by Zacks Equity Research
Perrigo (PRGO) completes previously announced acquisition of Ranir. The company raised guidance for adjusted earnings to include accretion of 10 cents from Ranir.
Are Options Traders Betting on a Big Move in Axovant (AXGT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Axovant (AXGT) stock based on the movements in the options market lately.
Axovant (AXGT) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Axovant (AXGT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Novavax' Shares Drop as FDA Advises Another Study for Resvax
by Zacks Equity Research
FDA recommends Novavax (NVAX) to conduct additional phase III study for its respiratory syncytial virus (RSV) vaccine candidate for infants, ResVax.
bluebird's Zynteglo Gets EU Conditional Marketing Approval
by Zacks Equity Research
bluebird bio (BLUE) announces that the EC has granted conditional marketing authorization to Zynteglo, its first gene therapy, for patients aged 12 years or older with TDT, who do not have a specific genotype.
Fibrocell Up on FDA Designation for Gene Therapy Candidate
by Zacks Equity Research
Fibrocell's (FCSC) gene therapy for a genetic skin disorder gets Regenerative Medicine Advanced Therapy designation, which expedites development process.
Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down
by Zacks Equity Research
Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.
Epizyme (EPZM) Shares Surge More Than 100% YTD: Here's Why?
by Zacks Equity Research
Epizyme's (EPZM) share price soars more than 100% year to date. The company is progressing well with its pipeline candidate, Tazmetostat.
Dynavax (DVAX) to Cut Jobs and Focus on Vaccine Business
by Zacks Equity Research
Dynavax (DVAX) announces restructuring measures to focus on vaccine business. The CEO of the company will retire on Aug 1, 2019.
Axovant Sciences Enters Oversold Territory
by Zacks Equity Research
Axovant Sciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Dr. Reddy's (RDY) Q4 Earnings Up Y/Y, Revenues Top Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) fourth-quarter earnings and sales increase year over year.
Regeneron (REGN) Gets FDA Nod for Eylea Label Expansion
by Zacks Equity Research
Regeneron's (REGN) Eylea gets FDA approval for label expansion to include patients of all stages with diabetic retinopathy.
Axovant (AXGT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Axovant (AXGT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.